Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRD-1001
- Development stage
- Preclinical
- Lead developer
- Medera
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SRD-1001 is an orally bioavailable small molecule currently in preclinical development by Medera Group (specifically through its subsidiary Sardocor) for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF). While the specific molecular target has not been publicly disclosed in the company's primary pipeline documentation, Medera's broader research focus centers on restoring calcium homeostasis in cardiomyocytes, often through the modulation of the SERCA2a (Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2a) pathway. The program aims to provide a convenient oral therapeutic option to improve cardiac contractility and clinical outcomes in patients suffering from chronic heart failure.
Beyond the preview
Go deeper on SRD-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRD-1001.